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Background: Over the past few years, the concurrent use of cisplatin-based chemotherapy and radiation therapy
has dramatically improved the local response and increased overall survival in early-stage cervical cancer. However,
for the advanced stages of the disease this standard treatment has proved insufficient. We investigated the capacity
of Mifepristone and ICI 182,780, which are anti-progestin and anti-estrogen drugs, respectively, to act as chemo-
radiosensitizing agents in cervical cancer cells and cervix xenografts.
Methods: The effect of chemo-radiation alone or combined with Mifepristone or ICI 182,780 was evaluated in HeLa
cells and with tumor growth in cervix xenografts. After concomitant chemo-radiotherapy, the effect of each of these
antihormonal agents on apoptosis (determined by Annexing V assay) and the cell cycle phases were determined by
flow cytometry. The expression of angiogenic factor VEGF in tumor samples was determined using quantitative
RT-PCR analysis of VEGF gene expression.
Results: Compared to radiation alone or radiation/cisplatin therapy, there was significantly higher cytotoxicity and a
greater antitumoral effect with the combined application of radiation/cisplatin and Mifepristone or ICI 182,780.
Analyses of the apoptosis and cell cycle demonstrated changes only with ICI, not with Mifepristone, when was
applied in combination with radiation/cisplatin. The analysis of VEGF mRNA expression levels in tumors at the end
of the study demonstrated a significant inhibition, compared to radiation only or the radiation/cisplatin treatment,
after concurrent chemo-radiotherapy and each one of the antihormonal drugs.
Conclusion: Mifepristone and ICI 182,780 may be potentially promising chemo-radiosensitizing compounds to be
used in combination with ionizing irradiation and cisplatin in the treatment of patients with advanced cervical cancer.
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Cervical cancer is still a major cause of morbidity and
mortality in women worldwide. In several low-income
countries this disease, if not treated in time, is one of the
most aggressive gynecological cancers. Although routine
screening programs have been implemented since 1975,
there continues to be an increased rate of new cases [1,2].
Human papillomavirus (HPV) has been proposed as an
etiological factor in the pathogenesis of this cancer [3].* Correspondence: pgarcia_lopez@yahoo.com.mx
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article, unless otherwise stated.At present, cervical cancer is considered as a potentially
curable disease in cases of early detection. Unfortunately
the majority of cases are diagnosed in the metastatic or
advanced stage, implying a worse prognosis that requires a
systemic treatment. Currently, the treatment for cervical
carcinoma is the combination of cisplatin-based chemo-
therapy and radiotherapy [4,5]. The introduction of
chemo-radiation for early stage cervical carcinoma led to
improvements in survival. Different studies have demon-
strated that chemo-radiotherapy lead to a significant
survival advantage of 10-15% at 5 years post-treatment
compared with radiotherapy alone for patients in stageed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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IIIA-IVA is still unfavorable [6-8].
Apart from their limited effectiveness in the advanced
stage of the disease, current chemotherapy and radio-
therapy have serious drawbacks. The administration of
cisplatin is associated with serious side effects, such as
nephrotoxic and neurotoxic events [9], and the effective-
ness of radiation therapy is limited by damage to the
normal tissue. Several studies have sought to find drugs
capable of potentiating the antiproliferative effect of
chemo-radiotherapy in cervical cancer. In spite of the
promising anti-tumoral results with the use of hydroxy-
urea, gemcitabine or taxanes as radiosensitizers, even
greater side effects have been found with these drugs.
Hence, ongoing efforts are necessary to further improve
the outcome with locally advanced cervical cancer by
maximizing the local response and patient survival.
One proposal of this work is to seek chemo- and
radio- sensitizer drugs with less adverse effects. Some
antihormonals, such as tamoxifen, raloxifene, medroxi-
progesterone, mifepristone and ICI 182,780, have been
used in the treatment of hormone-dependent cancers (e.g.,
breast, ovarian, prostate and endometrial). However,
these compounds have been poorly studied as chemo-
radiosensitizers in cervical cancer because this carcinoma
is traditionally considered not to respond to antihormo-
nal therapy [10]. Nevertheless, the mechanisms of action
of these antihormonal agents described in the literature
seem to hold promise in facilitating the response to
chemo-radiation in cervical cancer cells. Such mecha-
nisms include caspase activation, growth factor regula-
tion [11], anti-apoptotic proteins inhibition [12,13] and
apoptosis induction by p53 [14,15].
The possible role of mifepristone (MF) or ICI 182,780
(ICI) to enhance the cytotoxicity of cisplatin and the ef-
fectiveness of radiotherapy in cervical cancer treatment
has not been sufficiently explored. MF has activity on
progesterone and is a glucocorticoid receptor antagonist.
It has been used a chemosensitizing drug to modulate
the cytotoxic activity of doxorubicin [16], paclitaxel [17]
and cisplatin on ovarian cancer cells [18]. We previously
demonstrated that MF was able to enhance the cytotox-
icity of cisplatin in cervical cancer cells in-vitro and in-
vivo by increasing the intracellular and intratumoral
concentration of cisplatin [19]. Furthermore, we recently
reported a reduction in the rate of tumor growth when
MF was added to the temozolamide-radiation scheme in
glioblastoma xenografts [20]. Overall, this evidence sug-
gests that MF could play an important role as chemo-
and radiosensitizer.
In another study using cervical cancer cells [21], we
showed that the combination of cisplatin with the anti-
estrogen ICI induced the arrest of the cell cycle at the
G2/M phase. The failure of this control checkpoint maylead to genomic instability resulting in hypersensitivity
to radiation.
The aim of the present study was to evaluate whether
MF or ICI used simultaneously with cisplatin and radio-
therapy could show a chemo-radiosensitizer effect, in-
creasing the anti-proliferative effect in cervical cancer
cells and in xenostransplants when treated with cisplatin
and radiation. To correlate the mechanism of action of
these antihormonals in the modulation of the effects of
chemo-radiotherapy on tumor cells, an analysis of cell
cycle and apoptosis at different times was made (the lat-
ter evaluated by Annexin V binding assay). Additionally,
the growth of cervix xenotrasplants was correlated with
a decrease in VEGF gene expression.
Methods
Drugs and reagents
Cisplatin, Mifepristone, Chloroform, Trypsin and Sodium
Chloride were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). ICI 182,780 was obtained from Tocris Cookson,
Inc. (Balwin, MO, USA). Dulbecco’s modified Eagle’s
medium (DMEM), FCS (fetal calf serum), EDTA (Ethylene-
diaminetetracetic acid), Tris and SDS were obtained from
Gibco, BRL (Grand Island, NY, USA). High-quality water
employed to prepare solutions was obtained through of a
Milli-Q Reagent Water System Continental Water Systems
(El Paso, TX, USA). Taq DNA polymerase was purchased
from Invitrogen (Carlsbad, CA, USA).
Solutions
A stock solution (1 mg/mL) of cisplatin was prepared in
saline solution. ICI and MF were reconstituted in abso-
lute ethanol (stock solution). All standard solutions were
stored at −20°C until use.
Animals
Female athymic Balb-c nu/nu mice, between 6–8 weeks of
age, were supplied by the Instituto Nacional de Nutrición
(INCMNSZ), Mexico City, Mexico. All animals were kept
in a pathogen-free environment and fed ad lib. The proce-
dures for care and use of animals were approved by the
Ethics Committee of the Instituto Nacional de Cancerología
(INCan, Mexico City, Mexico) and all applicable institu-
tional and governmental regulations concerning the ethical
use of animals were followed.
Cell cultures
The HeLa human cervical cancer cell line was obtained
from ATCC (Rockville, Maryland, USA), and was rou-
tinely maintained as a monolayer in DMEM supple-
mented with 10% fetal bovine serum, and incubated at
37°C with high humidity in a 5% CO2 atmosphere. Cells
were harvested with 0.025% trypsin and 1 mM EDTA.
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Cells were seeded into 25 cm2 culture plates at a density
of 5×105 cells per well and pretreated for 3 days with
10 μM MF or ICI. Control cells were exposed only to
the vehicle (the final ethanol concentration never ex-
ceeded 1% v/v in treated or control samples). At the end
of the exposure period, the culture medium was re-
moved and fresh medium with 0.33 μM of cisplatin plus
MF or ICI was added. After 24 h the cells were irradi-
ated at 0.75 Gy using a 60Co irradiator (Theraton, Phoenix,
USA). Controls were handled in the same way as the irra-
diated cultures. Moreover, cells exposed only to the indi-
vidual treatments (with or without radiation) served as a
positive control. After exposure, cell survival was deter-
mined by the clonogenic assay.
Clonogenic cell survival assay
Surviving cells were analyzed for cytotoxic effects of
chemotherapy and/or irradiation treatments, according
to the establish method of the clonogenic assay [22].
Briefly, following exposure to radiation, the cells were
immediately rinsed, trypsinized, diluted, counted, and
seeded in triplicate at different cell densities in 25 cm2
plates, and then allowed to grow at 37°C for 2 weeks.
During this time colonies were formed from surviving
cells, and these colonies were fixed in 10% formaldehyde
and stained with a solution of crystal violet. Colonies of
50 cells or more were counted manually with a cell
counter (Bantex, USA). The survival rate was expressed
as the plating efficiency (PE), which is equal to the average
number colonies counted divided by the total number of
cells plated a calculation that normalized clonogenic sur-
vival. At least three independent experiments were per-
formed for each assay.
Cell cycle analysis
The cells (5 × 104) were synchronized and plated in spe-
cific medium following the previously described proto-
col. At 24, 48 and 72 h post-irradiation, the cultured
cells were harvested and washed twice with PBS, then
fixed with 70% (v/v) ethanol and stored at 4°C overnight.
Afterwards, ethanol was removed and the samples were
washed with PBS. Cellular DNA staining was performed
with Guava Cell Cycle Reagent for 30 min (Guava Tech-
nologies, Millipore, Hayward, CA, USA). The data were
collected and analysed by a Guava EasyCyte Flow cytometer
with use of GuavaSoft software (Millipore, Hayward, CA),
as a minimum 1×104 cells were acquired. At least three in-
dependent experiments were performed.
Annexin V staining assay for apoptosis
Phosphatidylserine externalization was analyzed using
the Guava Nexin Kit. Cells were plated and treated as
before mentioned, the Annexin V binding assay wasconducted at 24, 48 and 72 h post-irradiation. Cultured
cells were harvested and washed twice with PBS, and
then resuspended in Guava Nexin Reagent, containing
binding buffer, Annexin V-phycoerytrin (PE) and 7-
aminoactinomycin D (7-AAD), incubated for 20 min at
room temperature according to Guava protocol instruc-
tions (Guava Technologies, Millipore, Hayward, CA,
USA). Analysis was carried out by flow cytometry using
Guava EasyCyte, acquiring 5×103 cells. Annexin analysis
was performed with the GuavaSoft software (Millipore,
Hayward, CA). At least three independent experiments
were performed for each assay.
Tumor xenografts
Mice were subcutaneously (s.c) inoculated with 5×106
HeLa cells in both hind limbs. The limbs were selected
as the site for tumor growth to minimize irradiation to
organs. Weekly measurements of tumors were made
after inoculation. Two perpendicular diameters were
measured by using a caliper, and tumor volume was de-
termined by using the following relation: V = π/6 × (large
diameter × [short diameter]2). Once tumors had reached
approximately 150 mm3, the animals were pair-matched
in treatment and control groups and the treatments were
initiated. Each group consisted of 5–6 tumor-bearing
mice.
Irradiation procedure
Animals were anaesthetized with 1–3% isoflurane in
100% oxygen by using an animal anesthesia inhalation
unit (Bickford, Wales Center, NY, USA), and irradiated
with an orthovoltage X-ray unit (D3225, Gulmay Med-
ical Ltd., UK) as described previously [23]. Animals re-
ceived fractionated doses of 0.5 Gy per day for 20 days
(Monday through Friday for four weeks). The dose and
schedule were selected in accordance with the dose–
response curve constructed in a previous pilot study.
This curve showed a 10 Gy dose as the ED50 (dose of
radiation to achieve 50% growth inhibition). The X-ray
beam was centered on the tumor lobe by using one of
the different lead collimators [23], depending on the
tumor size at the moment of irradiation.
Chemo-radiotherapy in tumor xenografts
Animals selected for this study were divided into eight
groups (n = 5-6 each) including: A) radiation treatment
alone (0.5 Gy/day for 20 days); B) cisplatin treatment
alone (3 mg/kg/week for three cycles, i.p.); C) MF alone
(2 mg/kg/day, s.c.) or ICI alone (100 mg/kg/day, s.c.); D)
irradiation combined with cisplatin; E) irradiation com-
bined with MF or ICI; F) cisplatin combined with MF or
ICI; and G) three treatments combined (cisplatin/radi-
ation/ICI or cisplatin/radiation/MF). ICI and MF were
administered in three cycles during three weeks; each
Figure 1 Comparison of the clonogenic cell survival of HeLa
cells after individual treatments. The cells were treated with
0.75 Gy γ-irradiation, 0.33 μM cisplatin, MF and ICI (10 μM). Data are
represented as the mean ± SD of three independent experiments.
(*) Indicates a significant difference (p < 0.05) between the MF and
IC groups vs control group.
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Wednesday). Control animals received only the vehicle
and no irradiation. Mice were weighed and the tumor
volume was calculated every five days as previously de-
scribed. The experiment was conducted during 10 weeks,
at the end of which time all animals were weighed and
euthanized.
VEGF expression analysis by quantitative reverse
transcription-PCR (qRT-PCR)
The effect of MF or ICI on the expression of angiogenic
factors during concomitant chemo-radiotherapy was ex-
amined using qRT-PCR. VEGF expression levels in
tumor tissue from cervical carcinoma xenografs were
evaluated at the end of the study. Briefly, whole tumors
were lysed and the total RNA was isolated from each
tumor with a method based on guanidine isothiocyanate/
phenol/chloroform extraction using the TRIzol reagent
(Invitrogen Life Technologies), and then quantified with
UV spectroscopy. After quantification, 200 ng of the total
RNA was used in presence of the TaqMan® RNA-to-CT™
1-Step Kit (Applied Biosystems) to perform one-step RT-
PCR TaqMan Gene Expression Assays of vascular endo-
thelial growth factor A (VEGF-A) (Hs00900055_ml,
Applied Biosystems) by using a FAM probe and En-
dogenous Control Human GAPDH (4310884E, Applied
Biosystems) with VIC. Real-time quantification was per-
formed on a Spectrum 48 thermocycler Instrument
(ESCO, Micro Pte Ltd, Singapore).
PCR reactions were carried out in a total volume of
10 μl. The reaction conditions were as follows: pre-
incubation at 60°C for 15 minutes and 94°C for 5 mi-
nutes, followed by 40 cycles (amplification) of 94°C for
15 s and 60°C for 60s. Fluorescence emission spectra
were monitored and analyzed. PCR products were mea-
sured at the threshold cycle (Ct), at which time specific
fluorescence became detectable. The Ct was used for
kinetic analysis and was proportional to the initial num-
ber of target copies in the sample. Analysis of relative
gene expression was based on the 2-ΔΔCt method and
was carried out with three independent samples.
Statistical analysis
Values are reported as the mean ± SEM (standard error
of the mean). Statistical analysis was performed by using
one-way analysis of variance (ANOVA) to compare
tumor volumes between groups, using SPSS Base 20.0
software (SPSS Inc, Chicago, IL, USA). Differences were
statistically analyzed using multiple comparisons be-
tween groups. A log transformation was applied to data
to better satisfy the assumptions underlying the analysis.
The means and standard errors were computed from
untransformed data, but analysis of statistical signifi-
cance (p < 0.05) was based on transformed data. Whennecessary, comparison of the means was Bonferroni-
adjusted.Results
Growth inhibition in HeLa cells after chemo-radiotherapy
The dose and the schedule of each drug used in the
combination assays were selected in accordance with
dose–response curves constructed in a previous pilot
study. These curves showed that Cisplatin at 0.33 μM
and 10 Gy of radiation did not show any inhibitory effect
on the growth of HeLa cells when administered individu-
ally. However, it was observed a significant decrease (ap-
proximately 15%) with ICI or MF at 10 μM (Figure 1).
Cell survival, evaluated by clonogenic assay, is shown
for irradiation alone, irradiation with MF or ICI, cis-
platin with MF or ICI, cisplatin with irradiation, and cis-
platin with irradiation and MF or ICI (Figure 2).
Irradiation alone had not effect on the cell proliferation.
The antiproliferative effect was comparable when irradi-
ation was applied in combination with cisplatin, or when
either irradiation or cisplatin were combined with MF or
ICI (about 30-50% of cell survival compared to the con-
trol) (Figure 2A, B). However, when the cells were ex-
posed to a combination of irradiation, cisplatin and MF
or ICI, the proliferation was almost completely inhibited.
These experiments demonstrate that both agents can act
as a chemo-radiosensitizer in cervical cancer cells.
Figure 2 Clonogenic cell survival on HeLa cells after combined
treatments. A) Combinations with Mifepristone. B) Combinations
with ICI. All clonogenic assays were repeated in duplicate in at least
three independent experiments. Values represent the mean ± SD.
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To determine whether the effects of the combined treat-
ments, using cisplatin and irradiation with MF or ICI on
the proliferation of HeLa cells are mediated by inhibition
of cell cycle progression, the cell cycle phases of treated
cells were analyzed by flow cytometry at 24, 48 and
72 h. The results show that the G2/M phase was greater
for the treatment with iradiation/cisplatin/ICI than for
the treatment with only irradiation/cisplatin: 59.4% versus26.4% at 24 h (Figure 3A; p < 0. 001), 27% versus 22%
at 48 h (Figure 3B), and 34% versus 28% at 72 h
(Figure 3C).
To assess whether growth inhibition by irradiation/cis-
platin/ICI was mediated by apoptosis, HeLa cells were
stained with Annexin V-PE and 7-ADD for flow cyto-
metric analysis. Externalization of phosphatidylserine to
the outer surface of the plasma membrane is a distinct
phenomenon of early apoptosis. Analysis of Annexin V+/
7-AAD- cells (early and late apoptosis) showed that the ra-
diation/cisplatin/ICI treatment increased apoptosis at all
times measured with respect to control cells. This change
was particularly notable at 72 h, at which time the treat-
ment with radiation/cisplatin/ICI increased apoptosis by
23.8%, whereas treatment with only radiation/cisplatin
showed an increase of 2.36% increase compared to the
control (Figure 3D; p = 0.020). Therefore, the addition of
ICI arrested HeLa cells in G2/M phase at 24 and 48 h, and
later (at 72 h) and induced apoptosis. These data suggest
that G2/M arrested cells underwent apoptosis subse-
quently after treatment with radiation/cisplatin/ICI. On
the other hand, cells exposed to radiation/cisplatin/MF
did not show a significant change at any cell cycle phase
or in regard to the induction of apoptosis (Figures 3A-D).
Chemo-radiotherapy in tumor xenografts
Figure 4 shows tumor growth differences for the differ-
ent treatment combinations: individual treatment (cis-
platin, radiation or one of the antihormonals); dual
treatment (radiation or cisplatin with one of the antihor-
monals); triple treatment (radiation and cisplatin with
one of the antihormonals). Compared to the triple com-
bination of radiation/cisplatin/MF, there was a statistical
difference with the control group from the fourth week
on (p < 0.01), with the dual treatments from the eighth
week on (p < 0.05), and with the individual treatments
from the sixth week on (Figure 4A; p < 0.01). Whereas
compared to the triple combination of radiation/cis-
platin/ICI, there was a statistical difference with the con-
trol group from the fourth week on (p < 0.01), with the
dual treatments from the sixth week on (p < 0.05), and
with the individual treatments from the fourth week on
(Figure 4B; p < 0.05).
After ten weeks, it was observed that in the radiation/
cisplatin/MF and radiation/cisplatin/ICI groups, the tumor
volume was not different from its initial volume (Figure 5).
Contrarily, in the control group the tumor volume was
10-fold greater than the initial volume and in the radi-
ation/cisplatin group it was 5-fold greater.
Regarding the toxicity of treatments (Figure 6) no sig-
nificant change in weight was observed, although there
was a tendency to weight loss with the dual and triple
treatment groups. In the latter cases, the weight of the
animals was recovered by the end of the study.
Figure 3 Analysis of the cell cycle and apoptosis in HeLa cells after treatments. Cell-cycle distribution was expressed as the percentage of
surviving cells compared to the number of cells in the untreated control at 24 h (A), 48 h (B) and 72 h (C). Values represent the mean ± SD.
*p < 0.05 (comparing MF or ICI combined with cisplatin/radiation treatment to the treatment with only cisplatin/radiation). Apoptosis was measured by
surface AnV staining and flow cytometry, and it was considered positive for AnV+/PI- cells (D). Values represent the mean ± SD *p < 0.05 (comparing
MF or ICI combined with radiation/cisplatin to the treatment with only radiation/cisplatin).
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The effect of the triple treatments using cisplatin with
one of the antihormonal compound on the VEGF
mRNA levels was analysed in tumors at the end of the
study. The triple combination of radiation/cisplatin/MF
and radiation/cisplatin/ICI showed a statistically signifi-
cant lower level of VEGF than that found in the control
and radiation/cisplatin groups (Figure 7). Treatment
with cisplatin and irradiation did not modify VEGF
mRNA levels in tumors with respect to those from con-
trol group.
Discussion
Currently, treatment for advanced cervical cancer in-
volves the combination of cisplatin-based chemotherapy
and radiotherapy. However, this treatment generates re-
sistance and toxicity, either by the side effects caused by
cisplatin (neurotoxicity, myelotoxicity, nephrotoxicity
and ototoxicity) or the side effects caused by radiotherapy(damage to the normal tissue). Although this combination
(cisplatin/radiation) has proved to be effective in the early
stages of the disease, resulting in a patient survival rate of
around 90%, its use for patients in advanced stages has led
to a survival rate of only about 17% [7,8]. The poor
response to treatment is mainly caused by chemo-
radioresistant cells, which are capable of provoking
uncontrolled local tumor growth.
Different efforts have been done to improve chemora-
diotherapy for cervical cancer. However, there are few
studies have attempted to identify potential agents as
chemoradiosensitizer. Several compounds no-related to
anti-hormonals agents have showed a potential radiosen-
sitizer effect. Aspirin has showed radiosensitizing effect
on human cervical cancer cells, its mechanism was
mediated by Bcl-2, caspasas-3 pathway and p53 [24].
Plumbagin (naturally occurring naphtquinone) has been
studied as radiosensitizer on HeLa, SiHa and C33A cells;
results showed that this compound in combination with
Figure 4 Efficacy of antihormonal agents on HeLa cell tumors
treated with cisplatin or radiotherapy. HeLa cells were implanted
s.c. in both hind limbs of nude mice. Treatment was initiated when the
tumors reached 150 mm3. Mifepristone (A) or ICI (B) were administered
in combination with radiation, cisplatin, and radiation/cisplatin. B) ICI
was also administered in combination with radiation, cisplatin, and
radiation/cisplatin. As controls, tumor growth was determined for mice
treated only with the vehicle. Data are presented as the mean ± SEM of
five to six animals. (*) indicates a significant difference (p < 0.01)
between the triple combination groups vs control group; (#) and (†)
represent a significant difference vs the dual treatments (p < 0.05) and
individual treatments (p < 0.01) respectively.
Figure 5 Relative increase in tumor growth at the end of the
study with respect to the initial volume. *p < 0.05 comparing
initial vs final.
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the apoptosis pathway [25]. Tillmans et al. [26] evaluated
the radiosensitization of cervical cancer cell lines by ret-
inoic acid demonstrating that the effect involves the
HPV and p53 status. Furthermore, some drugs used inFigure 6 Percentage of change in body weight for mice treated
with cisplatin or radiotherapy, as well as for the combinations
with each of the two antihormonal agents. There was no
significant difference between groups. Data are presented as the
mean ± SEM of five to six animals.
Figure 7 Quantitative Real-Time PCR analysis of VEGF-A relative
expression in HeLa xenografts after each treatment. Analysis
was done on whole lysated tumors removed at week 10. (*) Indicates a
significant difference (p < 0.05) between the triple combination groups
vs control group.
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have showed a radiosensitizing effect; however greater
side effects can be found with these drugs.
In some types of hormone-dependent cancers, such as
breast and ovarian, anti- hormonal agents have been
used as chemo-sensitizer agents. However the applica-
tion of these compounds as chemo-radio-sensitizers has
been poorly studied in cervical cancer. Hence, the pur-
pose of the present study was to investigate whether MF
(an antiprogestin) or ICI (an antiestrogen) used simul-
taneously with cisplatin and radiotherapy could produce
a synergism and increase the anti-proliferative effect in a
cervical cancer cell line (HeLa) and in xenostransplants
treated with cisplatin and radiation.
Prior to evaluating the effect of each agent, cisplatin
and radiation doses were established for the combined
assays. The concentration of drugs applied individually
did not have a significant cytotoxic effect, thus a possible
synergistic effect would only be found when combina-
tions are applied. The individual dose of radiation and
cisplatin used in the present study showed no more than
25% of cell death. The concentration of the antihormo-
nals (10 μM), employed herein had no significant effect
when these agents were applied individually. When this
concentration, which is close to plasma concentrations
achievable in humans, was used in previous studies, the
anti- hormonal agent showed a chemo-sensitizer effect
for cisplatin in ovarian [13] and cervical carcinoma cell
lines [19,21], and for doxorubicin in hepatoma andleukemia cell lines [27]. This same concentration had a
chemosensitizing effect with doxorubicin in breast-
cancer cell lines [28] and a growth inhibition effect in
ovarian cell lines [29].
Results of the clonogenic assay showed that MF has a
chemo-radiosensitizer effect on the HeLa cell line. Cell
survival decreased nearly 100% when MF was added to
the standard treatment of cisplatin with radiation. It has
been reported that MF inhibits proliferation of certain
types of hormone-dependent cancers, such as breast
cancer positive for the progesterone receptor [30,31],
ovarian cancer [32,33], endometrium cancer [34], pros-
tate cancer [35] and gastric cancer [36]. Cervical cancer
does not respond to hormonal treatment. However, a
study conducted in our laboratory demonstrated that
when combined with MF, there was a significant
increase in the cytotoxicity of cisplatin in two cervical
cancer cell lines, HeLa and CaSki [19]. Tieszen CR et al.
[37] reported that growth inhibition of cancer cells by
antiprogestin MF is not dependent upon the expression
of nuclear progesterone receptors. They showed that MF
is capable of inhibiting the growth of in vitro cancer cells
derived from the nervous system, breast, prostate, ovary
and bone. Nearly all of these cancer cells lack the
expression of classic nuclear progesterone receptors.
As a chemosensitizing agent, MF has been used to
modulate the cytotoxic activity of doxorubicin, paclitaxel
and cisplatin, mostly in hormone-dependent cancers
such as breast cancer [16] and ovarian cancer [17,18].
However, there are few studies that demonstrate the role
of MF as chemo-radiosensitizer agent. We previously
reported that MF could improve the efficacy of chemo-
radiotherapy in glioblastoma xenografts [20].
The addition of MF to the standard treatment of
cisplatin with radiation did not induce significant
changes in the cell cycle distribution. Previous studies
have shown that MF induces G1-S blockage of the cell
cycle through inhibition of cdk2 activity in human ovar-
ian cancer cells [38]. A reduction in cdK2 activity has
been associated with the inhibition of the transcription
factor E2F1, which modulates S-phase progression [39].
The present study showed no changes in the G1 phase
of the cell cycle when MF was added to chemo-
radiotherapy treatment. Nevertheless, the dose of MF
used in our study was lower than that used in previous
reports. Furthermore, HeLa cell line shows low expres-
sion of hormonal receptors [21,40].
Many studies have reported the apoptotic effect of MF
on different tumor types [41-47]. Recently it was re-
ported that MF at low concentrations (<10 μM) could
enhance the chemosensitivity of cancer cells to cisplatin,
thus increasing the capability of this compound to induce
apoptosis in HeLa cells. The greater effect of cisplatin on
growth inhibition induced by MF was associated with the
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upregulation of the p53 protein [48]. Nevertheless, in the
present study there were no significant changes in apop-
tosis when MF was added.
Whereas cell survival was reduced with the addition of
MF to the cisplatin/radiation treatment (according to
the clonogenic assay), no significant change was found
in apoptosis or the cell cycle. The clonogenic assay in-
volves a longer exposure (15 days) to treatment than
that used in the analysis of apoptosis or the cell cycle
(24 to 72 h). This could be one of the causes of the ob-
served difference. On the other hand, when in the com-
bined MF/cisplatin/radiation treatment involved a higher
dose of cisplatin (3.3 μM), there was an increase in the
percentage of cells in the G2/M phase at 72 h (data not
shown). Therefore, exposure to MF for longer times or the
use of higher concentrations of cisplatin could sensitize
HeLa cell line by inducing G2/M arrest, the most radio-
sensitive cell cycle phase [49,50].
The results of the present study demonstrate that ICI
also has a chemo-radiosensitizing effect on the HeLa cell
line. The results show a decrease in survival with cells
exposed to the combined treatment of ICI/cisplatin/radi-
ation. The cytotoxic effect of the antiestrogen ICI in
combination with certain antineoplastic agents has been
clearly demonstrated in hormone-dependent breast can-
cer, reducing cellular proliferation and increasing cytotox-
icity [51]. There is also evidence that the combination of
cisplatin with ICI produces a synergistic effect, increasing
cellular cytotoxicity in a negative estrogen receptor ovar-
ian cancer line (A2780) [13]. A study conducted in our la-
boratory demonstrated that the combination of cisplatin
with ICI produces a synergistic antiproliferative effect in
cervical cancer cell lines. The effect of ICI on the cytotox-
icity of cisplatin could be mediated, at least in part, by cell
cycle arrest at the G2/M phase [21]. This correlates with
the results obtained in the present study, where analysis of
the cell cycle at 24 hours showed an increase in the per-
centage of cells arrested at G2/M when the ICI/cisplatin/
radiation treatment was administered. Furthermore, there
was an induction of apoptosis at 72 h. Therefore, the
pathway of ICI to sensitize HeLa cell line to chemo-
radiotherapy, is G2/M arrest preceding apoptosis, which
may be a mechanism for its inhibitory effects on growth
of the cancer cells. With the MF/cisplatin/radiation treat-
ment, we hypothesize that the cisplatin dose should have
been greater in order to arrest the cell cycle at the G2/M
phase and induce apoptosis. The activity of MF appears to
depend on the time of exposure to the treatment or the
concentration of cisplatin used.
The response biological to progesterone is mediated
by two isoforms of the progesterone receptor, PR-A and
PR-B. In most cell lines such as MCF-7 (breast cancer
cells), CV-1 (monkey kidney fibroblast), and HeLa (cervicalcarcinoma cells), PR-A functions as a transcriptional
repressor, whereas PR-B functions as a transcriptional ac-
tivator of progesterone-responsive genes [52]. Further-
more, it was reported that PR-A but not PR-B, in the
presence of either progesterone or anti-progestin, inhib-
ited ER-mediated transcriptional activity [53]. The same
authors have reported that mifepristone was capable of
functioning as an antagonist of ER only in the presence
of PR-A in MCF-7 cells [52]. We previously reported that
ERα and PR-AB gene levels in HeLa cells were relatively
low compared to those observed in MCF-7 cells [21];
however, ICI was able to downregulated ER and PR
genes, demonstrating a light ligand-receptor interaction.
It is possible that MF could show similar results and its
effect chemo-sensitization can be explained partially by
this mechanism. Further studies will need to be per-
formed to confirm this hypothesis.
In the present study we also evaluated whether there
is an improvement in the response of xenotransplants of
cervix in vivo with the addition of MF or ICI to the
standard therapy of cisplatin and radiotherapy. We ob-
served significant differences in tumor volume between
the treatments. When the MF or ICI were combined
with cisplatin, the effect was comparable to that of the
standard treatment (cisplatin/radiation). However, there
was a notable reduction in the tumor growth- rate when
MF or ICI was added to the cisplatin/radiation scheme,
suggesting that MF and ICI play an important role in
the chemo-radiosensitization not only in- vitro but also
in- vivo. When we evaluated the VEGF expression in the
xenografts at the end of the study, we observed that both
antihormonal agents decrease VEGF production. How-
ever, the effect was more evident with MF, suggesting
that VEGF down-regulation is one of the mechanisms
by this compound acts in combination with cisplatin/
radiation.
Other mechanisms independent of ER/PR that could
be involved in the chemoradiosensitizing effect of MF
and ICI are the decreasing the insulin-like growth factor
receptor (IGF-1), decreasing transforming-growth factor-
β1 (TGF-β1) or loss c-fos expression.
On the other hand, it has reported that some tumour
suppressor genes are involved in the regulation of angio-
genesis. One of them, p53, has been shown to be associ-
ated with VEGF in non-small cell lung cancer [54]. The
induction of VEGF gene expression by hypoxia in tumor
cells involves both an increase in the rate of gene tran-
scription mediated by HIF-1 (hypoxia-inducible factor),
and an enhancement of the stability of VEGF mRNA.
Transcription of VEGF mRNA is also induced by a var-
iety of growth factors and cytokines, including PDGF
(platelet-derived growth factor), EGF (Epidermal growth
factor), TNFα (tumor necrosis factor), TGF-β1 (Tumoral
growth factor), and IL-1β (interleukin) [55]. Also other
Segovia-Mendoza et al. BMC Cancer  (2015) 15:21 Page 10 of 11genes as Bcl2 have been associated with neo-angiogenesis
and a worse prognosis [56]. Moreover the loss of intra-
crine VEGF signaling leads to an increase in spontaneous
apoptosis and chemosensitivity. These effects were medi-
ated via upregulation of the proapoptotic mediators as
caspase-3, and Bax [56].
Recent studies have showed that tumor cells express
TLRs (Toll-like receptors), and this expression can facili-
tate the tumor development [57]. However, the relation-
ship between TLR-8 and cervical cancer has been little
studied. Recently, it has been reported the involvement
of TLR-8 and its relationship with VEGF in cervical can-
cer [58]. The authors demonstrated increased expression
of TLR-8 in HeLa cells and in cervical cancer tissue
from patients; in this study also was evaluated the cor-
relation between TLR-8 expression and two genes asso-
ciated to the pathogenesis of cancer like Bcl-2 and
VEGF. They found a positive correlation between TLR-8
and Bcl2 or VEGF expression both in cervical cancer tis-
sues as well as HeLa cells. These results suggest that
TLR-8 may be a therapeutic target in cervical cancer
and its ligand can modulate the response of chemother-
apy or radiotherapy. According to our results, it would
be interesting to see in future studies, if the pathway
TLR-8 is involved in the low expression of VEGF by the
triple combinations of radiation/cisplatin/MF and radi-
ation/cisplatin/ICI.
Finally, the lack of significant change in body weight
of animals, suggest that both Mifepristone and ICI could
be safely administered at these doses.
Conclusions
The present study shows that the addition of Mifepristone
or ICI improves chemo-radiotherapy treatment. It is pos-
sible that either of these antihormonal treatments sensi-
tizes to HeLa cell line by inducing G2/M arrest, the most
radiosensitive cell cycle phase, and by enhancing the cap-
acity of cisplatin to induce apoptosis. Hence, the results
strongly suggest that either antihormonal agent, when
used in combination with cisplatin and radiation, could
have potential as a chemo-radio-sensitizer for cervical
cancer treatment.
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